Fox Run Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Fox Run Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$277K	Buy	+16,028	New	+$220K	0.05%	704
2026 Q1	–	Sell	-33,724	Closed	-$425K	–	886
2025 Q4	$425K	Buy	+33,724	New	+$386K	0.07%	565
2025 Q1	–	Sell	-20,435	Closed	-$162K	–	896
2024 Q4	$162K	Buy	20,435 +8,342	+69%	+$70K	0.03%	776
2024 Q3	$101K	Buy	+12,093	New	+$94.6K	0.02%	741
2021 Q3	–	Sell	-14,184	Closed	-$73K	–	455
2021 Q2	$73K	Buy	+14,184	New	+$80.6K	0.07%	325
2019 Q3	–	Sell	-24,749	Closed	-$177K	–	352
2019 Q2	$177K	Buy	+24,749	New	+$253K	0.12%	377
2018 Q3	–	Sell	-13,872	Closed	-$228K	–	560
2018 Q2	$228K	Buy	+13,872	New	+$243K	0.07%	533

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Fox Run Management's AMRX Position: Q2 2026 in Review

Fox Run Management opened a new position in Amneal Pharmaceuticals (AMRX) in Q2 2026: 16,028 shares worth $277K. The stake represents 0.05% of the portfolio and ranks #704 among its holdings. This is a return to the name: Fox Run Management previously reported a position in AMRX as recently as Q4 2025.

Fox Run Management first reported a position in AMRX in Q2 2018 and has held it in 7 quarters since. The position peaked at $425K in Q4 2025. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Fox Run Management held 16,028 shares of Amneal Pharmaceuticals worth $277K as of Q2 2026.
Amneal Pharmaceuticals was a new Fox Run Management position in Q2 2026.
Amneal Pharmaceuticals made up 0.05% of Fox Run Management's portfolio in Q2 2026, its #704 holding.
Fox Run Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 7 quarters since.
Fox Run Management's Amneal Pharmaceuticals position peaked at $425K in Q4 2025.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.